Build-vs-Buy Manufacturing Strategy

Overview

The strategic decision framework for biopharmaceutical companies on whether to build internal manufacturing capacity, outsource to CDMOs, partner, or adopt hybrid models, driven by cost, scale, flexibility, and pipeline modality complexity. The build-vs-buy manufacturing decision hinges on four parameters — cost, scale, flexibility, and pace of pivoting between programs — with flexibility identified as the most critical for companies with evolving early clinical pipelines where programs frequently change direction. A preferred hybrid build-buy model requires a CDMO partner equally committed to the mission of bringing medicines to patients and willing to act as a thought partner and knowledge collaborator, not merely a manufacturing service provider. (Segment 2 (05:00-10:00))